Seattle, June 22, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the North America, Europe, and Australia peanut allergy treatment market is estimated to be valued at US$ 1,252.6 million in 2022 and is expected to exhibit a CAGR of 11.7% during the forecast period (2022-2030).
Key Trends and Analysis of the North America, Europe, and Australia Peanut Allergy Treatment Market:
Key trends in market include research and development for treatment of peanut allergy which is expected to drive North America, Europe, and Australia peanut allergy treatment market growth over the forecast period. For instance, on January 26, 2022, Allergy Therapeutics PLC., a pharmaceutical company, announced that the company is expected to initiate the Phase 1 clinical trial for peanut allergy in April 2022, in the U.S.
Moreover, increasing awareness campaigns for peanut allergy treatment by market players which is expected to propel the North America, Europe, and Australia peanut allergy treatment market growth over forecast period. For instance, in August 2021, The Kraft Heinz Company, a food products company, announced the campaign called “Protection for Peanuts”, a fund for patients to buy epinephrine injections for the treatment of peanut allergy in Canada.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5041
Key Market Takeaways:
North America, Europe, and Australia peanut allergy treatment market is expected to exhibit a CAGR of 11.7% during the forecast period due to increasing research and development for peanut allergy treatment by key players which is expected to drive North America, Europe, and Australia peanut allergy treatment market over the forecast period. For instance, in December 2021, DBV Technologies S.A., a clinical stage biopharmaceutical company, announced that the company initiated a new, pivotal Phase 3 clinical study for a modified Viaskin Peanut patch in children in the intended patient population. DBV Technologies S.A., also issued an update on the marketing authorization application for Viaskin Peanut with the European Medicines Agency (EMA).
Among Drug Type, Epinephrine segment is estimated to hold a dominant position in the North America, Europe, and Australia peanut allergy treatment market in 2022 owing to increasing number of drug approvals from regulatory bodies. For instance, in November 2017, kaléo, a privately-held pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for AUVI-Q (epinephrine injection, USP) 0.1 mg, the first and only epinephrine autoinjector (EAI) specifically designed for the treatment of life-threatening allergic reactions including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds (7.5 to 15 kilograms), who are at risk for or have a history of serious allergic reactions.
On the basis of Route of Administration, Parenteral segment is estimated to hold a dominant position in the North America, Europe, and Australia peanut allergy treatment market in 2022 due to increasing number of product launches by key market players. For instance, in December 2016, Viatris Inc. (Mylan N.V.), a healthcare company, announced the launch of the authorized generic product for EpiPen (epinephrine injection, USP) auto-injector. EpiPen is an auto injector indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis, allergens, idiopathic, and exercise induced anaphylaxis
Competitive Landscape:
Key players operating in the North America, Europe, and Australia peanut allergy treatment market are, DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., and Stallergenes Greer Ltd.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/5041
Market Segmentation:
- North America, Europe, and Australia Peanut Allergy Treatment Market, By Drug Type :
- Epinephrine
- Antihistamine
- Loratadine
- Diphenhydramine
- Others
- Palforzia
- Pipeline Drugs
- Viaskin Peanut
- Ligelizumab
- CA002
- PRT120
- Dupilumab
- North America, Europe, and Australia Peanut Allergy Treatment Market, By Route of Administration :
- Oral
- Parenteral
- Intranasal
- Epicutaneous
- North America, Europe, and Australia Peanut Allergy Treatment Market, By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America, Europe, and Australia Peanut Allergy Treatment Market, By Region:
- North America
- By Country
- U.S.
- Northeast
- Southwest
- West
- Southeast
- Midwest
- Canada
- By Country
- Europe
- By Country
- U.K.
- Germany
- France
- Italy
- Spain
- Switzerland
- Netherlands
- Austria
- Czech & Slovakia
- Rest of Europe
- By Country
- Australia
- North America
Related Market Intelligence Reports:
Chronic Myeloid Leukemia Treatment Market, by Drug Type (Tyrosine Kinase Inhibitors (Imatinib (Gleevec), Dasatinib (Sprycel), Nilotinib (Tasigna), Bosutinib (Bosulif), Ponatinib (Iclusig), Asciminib (Scemblix), and Others), Antimetabolites, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Peanut Allergy Vaccine Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
